

RIO participant meeting 26 May 2022



Simon Collins,
www.i-Base.info



Imperial College
London



Background

- RIO is one of the few cure-related studies that could directly benefit participants.
- Early research - but with very interesting results in a few earlier studies.
- Potential benefits seem to balance potential risks for someone who wants to be involved.
- Studies at CROI continue to look exciting.

Update

- Enrolment is after COVID should be helped by inclusion of new clinical sites.
- Roll-over access to a second dose for some people is an additional benefit.
- Good ongoing results - including safety review.
- Rebound during ATI: risk of reinfection and to partners: please take the time off ART seriously.

Questions

- All questions are good questions 😊
- bNAbs? ... RIO? ...
CROI studies... monkeypox....?